

Challenging Cases in Non-Hodgkin Lymphoma

Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty

The third of 6 integrated symposia in an oncology curriculum

CNE INFORMATION

TARGET AUDIENCE

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL).

OVERVIEW OF ACTIVITY

Taken together, it is estimated that approximately 148,040 new lymphoid and myeloid cancer cases were identified in the United States in the year 2012, and 54,380 individuals died from these diseases. Of importance, there are currently more than 50 drug products labeled for use in the management of hematologic cancers with more than 60 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors, and the dynamic therapeutic NHL environment dictates that all pivotal members of the oncology/hematology care team be able to appropriately identify the benefits and risks of the plethora of emerging treatment options.

These video proceedings from the third part of a 6-part integrated CNE curriculum originally held at the 2013 ONS Annual Congress feature discussions with leading NHL investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario. By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with NHL.

LEARNING OBJECTIVES

- Identify the unique risks and benefits associated with commonly used therapeutic approaches for patients with newly diagnosed or relapsed/refractory NHL/chronic lymphocytic leukemia (CLL) to facilitate appropriate patient counseling.
- Formulate supportive care strategies to manage the side effects associated with these interventions to maximize patient quality of life while minimizing the potential for treatment discontinuation.
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with NHL/CLL to optimize clinical and quality-of-life outcomes.
- Recall ongoing trials of investigational approaches and agents in NHL and CLL, and consent and refer patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

This educational activity for 1.5 contact hours is provided by Research To Practice during the period of July 2013 through July 2014.

HOW TO USE THIS CNE ACTIVITY

This CNE activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSNHL2013/Video/CNE.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Andrew M Evens, DO, MSc

Associate Professor of Medicine
Deputy Director for Clinical and Translational Research
CRO Medical Director
UMass Memorial Cancer Center
Division of Hematology/Oncology
Director, Lymphoma Program
The University of Massachusetts Medical School
Worcester, Massachusetts

Advisory Committee: Millennium: The Takeda Oncology Company, Seattle Genetics, Spectrum Pharmaceuticals Inc;

Contracted Research: Millennium: The Takeda Oncology Company, ZIOPHARM Oncology Inc.

Amy Goodrich, CRNP-AC

Nurse Practitioner
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

No real or apparent conflicts of interest to report.

Mollie Moran, MSN, CNP, AOCNP

The James Cancer Hospital at The Ohio State University
Columbus, Ohio

No real or apparent conflicts of interest to report.

Lauren C Pinter-Brown, MD

Director, UCLA Lymphoma Program
Clinical Professor of Medicine
Geffen School of Medicine at UCLA
Los Angeles, California

Consulting Agreements: Celgene Corporation, Millennium: The Takeda Oncology Company, Spectrum Pharmaceuticals Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec and Teva Oncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center

Last review date: July 2013

Expiration date: July 2014

- Abramovits W et al. **Pralatrexate (Folotyn).** *Skinmed* 2012;10(4):244-6.
- Bolden JE et al. **Anticancer activities of histone deacetylase inhibitors.** *Nat Rev Drug Discov* 2006;5(9):769-84.
- Cang S et al. **Novel CD20 monoclonal antibodies for lymphoma therapy.** *J Hematol Oncol* 2012;5:64.
- Coiffier B et al. **Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.** *J Clin Oncol* 2012;30(6):631-6.
- Coiffier B et al. **Romidepsin induces durable responses in patients with peripheral T-cell lymphoma: GPI-06-0002 study update.** *Proc ASH* 2012;[Abstract 3641](#).
- Coutre SE et al. **Combinations of the selective phosphatidylinositol 3-kinase-delta (PI3Kdelta) inhibitor GS-1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): Results from a Phase I study.** *Proc ASH* 2012;[Abstract 191](#).
- Flinn IW et al. **An open-label, randomized study of bendamustine and rituximab (BR) compared with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line treatment of patients with advanced indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL): The Bright study.** *Proc ASH* 2012;[Abstract 902](#).
- Fowler NH et al. **Lenalidomide and rituximab for untreated indolent lymphoma: Final results of a Phase II study.** *Proc ASH* 2012;[Abstract 901](#).
- Kahl BS et al. **Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): A randomized Phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma.** *Proc ASH* 2011;[Abstract LBA-6](#).
- Kluin-Nelemans HC et al. **Treatment of older patients with mantle-cell lymphoma.** *N Engl J Med* 2012;367(6):520-31.
- Kwon HJ et al. **Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis.** *Int J Cancer* 2002;97(3):290-6.
- Maloney DG. **Anti-CD20 antibody therapy for B-cell lymphomas.** *N Engl J Med* 2012;366(21):2008-16.
- O'Connor OA et al. **Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study.** *J Clin Oncol* 2011;29(9):1182-9.
- Paramore A, Frantz S. **Bortezomib.** *Nat Rev Drug Discov* 2003;2(8):611-2.
- Pearl MJ et al. **Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.** *Proc Nat Acad Sci* 2005;102(10):3697-702.
- Press OW, Palanca-Wessels MC. **Selection of first-line therapy for advanced follicular lymphoma.** *J Clin Oncol* 2013;31(12):1496-8.
- Rummel MJ et al. **Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial.** *Lancet* 2013;381(9873):1203-10.
- Salles G et al. **Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial.** *Lancet* 2010;377(9759):42-51.
- Swerdlow SH et al. **WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.** Lyon: IARC; 2008.
- Wang Y et al. **FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.** *Biochem Biophys Res Commun* 2007;356(4):998-1003.
- Wierda WG. **Making advances in first-line chronic lymphocytic leukemia treatment.** *J Clin Oncol* 2012;30(26):3162-4.
- Wiestner A. **Targeting B-cell receptor signaling for anticancer therapy: The Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.** *J Clin Oncol* 2013;31(1):128-30.